Broad spectrum antivirals The group identified active compounds against emerging viruses (i e Zika, Dengue, SARS COV 2). Analysis of novel foods and circular economy Study the upcycling by products in insects Analysis of the influence insect derived components in the prevention of cardiovascular diseases
The research group works in: Development and use of pharmacological and biochemical in vitro models (primary cells, cell cultures, isolated tissues/organs) for: 1.Pharmacology/safety pharmacology/cardiovascular toxicology of newly synthesized compounds, extracts, or purified compounds of natural origin. 2.Recycling and valorization of agricultural and food by-products: evaluation of protective properties against cardiovascular diseases.
Our research activity adopts a ONE HEALTH approach while applying post genomics (proteomics, metabolomics), cell biology, biochemistry, computational biochemistry and AI in Life Sciences, sustainable pharmaceuticals and circular bioeconomy.
The research activity is focused on basic research projects based on the ONE HEALTH principle . The activity mainly aims to evaluate the benefits for human health of compounds extracts of ornamental plants or foods with particular attention to the principles of local biodiversity and bioeconomy
The research activities of the BioStructLab are focus on gene manipulation by recombinant DNA technique, production of biological macromolecules ( RNA and DNA), and structural characterization by structural biology techniques The
The research group is focused on two key areas, synthetic organic chemistry and computational chemistry, which are highly complementary and in complete synergy with each other. the research group is interested in the development of new chemical methodologies in the medicinal chemistry context and in the study of the interaction between the drug and its macromolecular target
The invention consists of a smart, inexpensive and biocompatible nanomaterial with custom-designed bioactivity.
The patent application protects nontoxic small molecules (glycomimetics), easily obtained from natural compounds (carbohydrates), which can be used for personalized treatment of glycan-related diseases
The invention relates to a 'Clustered Regularly Interspersed Short Palindromic Repeat (CRISPR) CRISPR associated (Cas)’ (CRISPR-Cas) system targeting a genome sequence in a eukaryotic cell, i.e. a system useful for making modifications within the cell genome.
The invention refers to the use of an engineered 'Clustered Regularly Interspersed Short Palindromic Repeat (CRISPR)-CRISPR associated (Cas)’ (CRISPR-Cas) technology targeting a sequence mutated at one or more loci in the genome of a given eukaryotic cell
